Preclinical data shows Dihexa can be millions of times more potent than BDNF in driving synapse growth
It is often accompanied by chronic fatigue, muscle loss, osteoporosis, depressive states or increased risk of cardiometabolic disorders
In a 2025 analysis of 1,124 GLP-1 users without diabetes: 94% persisted at 12 weeks, and 84% at 24 weeks compared to typical rates as low as 33% Users who remained on GLP-1s through 24 weeks achieved 12.1% weight loss, while early discontinuers lost 7.4% resulting in a 64% relative improvement Omadas companion support model helped members reach clinical trial-level outcomes in real-world settings Outcomes-based contracting This model shifts financial risk from the employer to the vendor by tying payment to the achievement of predefined clinical outcomes
It works by helping regulate appetite, slow digestion, and improve blood sugar control making it easier to feel full, reduce cravings, and lose weight safely
Start Slowly : Many side effects of semaglutide, like nausea, improve as your body adjusts
Food and Drug Administration (FDA) approved Rybelsus, the oral version of Semaglutide from Novo Nordisk, for reducing the risk of major cardiovascular events in adults with Type 2 diabetes mellitus (T2DM) who are at high cardiovascular risk, including those without prior heart attack or stroke
)
